{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:39:22Z","timestamp":1786991962472,"version":"build-2736575974"},"reference-count":27,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,3,2]],"date-time":"2020-03-02T00:00:00Z","timestamp":1583107200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010414","name":"Health Research Board","doi-asserted-by":"publisher","award":["TRA 201115"],"award-info":[{"award-number":["TRA 201115"]}],"id":[{"id":"10.13039\/100010414","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001602","name":"Science Foundation Ireland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001602","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["celltherapyjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytotherapy"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.jcyt.2020.02.007","type":"journal-article","created":{"date-parts":[[2020,4,6]],"date-time":"2020-04-06T07:41:00Z","timestamp":1586158860000},"page":"313-321","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["Autologous bone marrow mesenchymal stromal cell therapy for \u201cno-option\u201d critical limb ischemia is limited by karyotype abnormalities"],"prefix":"10.1016","volume":"22","author":[{"given":"Sara Azhari","family":"Mohamed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Howard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"McInerney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amjad","family":"Hayat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0631-103X","authenticated-orcid":false,"given":"Janusz","family":"Krawczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Naughton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Finnerty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0740-2224","authenticated-orcid":false,"given":"Miriam","family":"Holohan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aoife","family":"Duffy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tony","family":"Moloney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eamon","family":"Kavanagh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Burke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Liew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Tubassam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stewart Redmond","family":"Walsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"O'Brien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jcyt.2020.02.007_bib0001","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1016\/j.jvs.2006.12.037","article-title":"Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II)","volume":"45","author":"Norgren","year":"2007","journal-title":"J Vasc Surg"},{"issue":"3","key":"10.1016\/j.jcyt.2020.02.007_bib0002","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.ejvs.2010.05.005","article-title":"The next 10 years in the management of peripheral artery disease: perspectives from the \u2018PAD 2009\u2019 Conference","volume":"40","author":"Norgren","year":"2010","journal-title":"Eur J Vasc Endovasc Surg"},{"issue":"6s","key":"10.1016\/j.jcyt.2020.02.007_bib0003","doi-asserted-by":"crossref","first-page":"3S","DOI":"10.1016\/j.jvs.2019.02.016","article-title":"Global vascular guidelines on the management of chronic limb-threatening ischemia","volume":"69","author":"Conte","year":"2019","journal-title":"J Vasc Surg"},{"issue":"9501","key":"10.1016\/j.jcyt.2020.02.007_bib0004","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1016\/S0140-6736(05)67704-5","article-title":"Bypass versus angioplasty in severe ischaemia of the leg (BASIL): Multicentre, randomised controlled trial","volume":"366","author":"Bradbury","year":"2005","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.jcyt.2020.02.007_bib0005","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.biocel.2003.11.001","article-title":"Mesenchymal stem cells: clinical applications and biological characterization","volume":"36","author":"Barry","year":"2004","journal-title":"Int J Biochem Cell Biol"},{"issue":"5","key":"10.1016\/j.jcyt.2020.02.007_bib0006","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1080\/14653240500319234","article-title":"Clarification of the nomenclature for MSC: the International Society for Cellular Therapy position statement","volume":"7","author":"Horwitz","year":"2005","journal-title":"Cytotherapy"},{"issue":"1","key":"10.1016\/j.jcyt.2020.02.007_bib0007","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.diabres.2010.12.010","article-title":"Comparison of bone marrow mesenchymal stem cells with bone marrow-derived mononuclear cells for treatment of diabetic critical limb ischemia and foot ulcer: a double-blind, randomized, controlled trial","volume":"92","author":"Lu","year":"2011","journal-title":"Diabet Res Clin Pract"},{"issue":"4","key":"10.1016\/j.jcyt.2020.02.007_bib0008","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/scrt119","article-title":"Therapeutic potential for mesenchymal stem cell transplantation in critical limb ischemia","volume":"3","author":"Liew","year":"2012","journal-title":"Stem Cell Res Ther"},{"issue":"5","key":"10.1016\/j.jcyt.2020.02.007_bib0009","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1089\/rej.2009.0872","article-title":"Targeting nonhealing ulcers of lower extremity in human through autologous bone marrow-derived mesenchymal stem cells","volume":"12","author":"Dash","year":"2009","journal-title":"Rejuv Res"},{"issue":"7","key":"10.1016\/j.jcyt.2020.02.007_bib0010","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1253\/circj.CJ-11-1135","article-title":"Safety and effect of adipose tissue-derived stem cell implantation in patients with critical limb ischemia\u2014a pilot study","volume":"76","author":"Lee","year":"2012","journal-title":"Circ J"},{"issue":"1","key":"10.1016\/j.jcyt.2020.02.007_bib0011","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/1479-5876-11-143","article-title":"A double blind randomized placebo controlled phase I\/II study assessing the safety and efficacy of allogeneic bone marrow derived mesenchymal stem cell in critical limb ischemia","volume":"11","author":"Gupta","year":"2013","journal-title":"J Transl Med"},{"issue":"6","key":"10.1016\/j.jcyt.2020.02.007_bib0012","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1177\/0003319710364213","article-title":"Combination stem cell therapy for the treatment of severe limb ischemia: safety and efficacy analysis","volume":"61","author":"Lasala","year":"2010","journal-title":"Angiology"},{"issue":"10","key":"10.1016\/j.jcyt.2020.02.007_bib0013","doi-asserted-by":"crossref","first-page":"650","DOI":"10.7326\/0003-4819-153-10-201011160-00007","article-title":"Autologous mesenchymal stem cells foster revascularization of ischemic limbs in systemic sclerosis: a case report","volume":"153","author":"Guiducci","year":"2010","journal-title":"Ann Int Med"},{"issue":"5","key":"10.1016\/j.jcyt.2020.02.007_bib0014","first-page":"444","article-title":"Intramuscular transplantation of G-CSF-mobilized CD34+ cells in patients with critical limb ischemia: a phase I\/IIa, multicenter, single-blinded, dose-escalation clinical trial","volume":"67","author":"Kawamoto","year":"2009","journal-title":"Stem Cells"},{"issue":"11","key":"10.1016\/j.jcyt.2020.02.007_bib0015","first-page":"2857","article-title":"Cell therapy for critical limb ischemia: a meta-analysis of randomized controlled trials","volume":"27","author":"Liew","year":"2016","journal-title":"Angiology"},{"issue":"4","key":"10.1016\/j.jcyt.2020.02.007_bib0016","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1080\/14653240600855905","article-title":"Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement","volume":"8","author":"Dominici","year":"2006","journal-title":"Cytotherapy"},{"issue":"5","key":"10.1016\/j.jcyt.2020.02.007_bib0017","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.aanat.2009.07.001","volume":"191","author":"Schwinger","year":"2009","journal-title":"Ann Anat"},{"key":"10.1016\/j.jcyt.2020.02.007_bib0018","article-title":"Gene therapy for peripheral arterial disease","volume":"10","author":"Liew","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"10.1016\/j.jcyt.2020.02.007_bib0019","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1007\/PL00001974","article-title":"Angiogenesis and vasculogenesis. Therapeutic approaches for stimulation of post-natal neovascularization","volume":"25","author":"Kalka","year":"2000","journal-title":"Herz"},{"issue":"5302","key":"10.1016\/j.jcyt.2020.02.007_bib0020","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1126\/science.275.5302.964","article-title":"Isolation of putative progenitor endothelial cells for angiogenesis","volume":"275","author":"Asahara","year":"1997","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.jcyt.2020.02.007_bib0021","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/S1000-1948(08)60031-3","article-title":"Autologous transplantation of bone marrow mesenchymal stem cells on diabetic patients with lower limb ischemia","volume":"23","author":"Debin","year":"2008","journal-title":"J Med Coll PLA"},{"issue":"6","key":"10.1016\/j.jcyt.2020.02.007_bib0022","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1038\/mt.2012.52","article-title":"Cellular therapy with Ixmyelocel-T to treat critical limb ischemia: the randomized, double-blind, placebo-controlled RESTORE-CLI trial","volume":"20","author":"Powell","year":"2012","journal-title":"Mol Ther"},{"issue":"9","key":"10.1016\/j.jcyt.2020.02.007_bib0023","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1111\/dme.13985","article-title":"Impact of severe diabetic kidney disease on the clinical outcome of autologous cell therapy in people with diabetes and critical limb ischaemia","volume":"36","author":"Dubsk\u00fd","year":"2019","journal-title":"Diabet Med"},{"issue":"6","key":"10.1016\/j.jcyt.2020.02.007_bib0024","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.jcyt.2016.02.009","article-title":"Safety and efficacy of cell-based therapy on critical limb ischemia: a meta-analysis","volume":"18","author":"Ai","year":"2016","journal-title":"Cytotherapy"},{"issue":"8","key":"10.1016\/j.jcyt.2020.02.007_bib0025","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1182\/blood-2009-05-219907","article-title":"Clinical-grade production of human mesenchymal stromal cells: occurrence of aneuploidy without transformation","volume":"115","author":"Tarte","year":"2010","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jcyt.2020.02.007_bib0026","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.stem.2011.12.005","article-title":"Limited acquisition of chromosomal aberrations in human adult mesenchymal stromal cells","volume":"10","author":"Senseb\u00e9","year":"2012","journal-title":"Cell Stem Cell"},{"issue":"7","key":"10.1016\/j.jcyt.2020.02.007_bib0027","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.jcyt.2013.03.005","article-title":"Risk of tumorigenicity in mesenchymal stromal cell-based therapies\u2014bridging scientific observations and regulatory viewpoints","volume":"15","author":"Barkholt","year":"2013","journal-title":"Cytotherapy"}],"container-title":["Cytotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324920300621?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324920300621?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T01:40:56Z","timestamp":1761442856000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1465324920300621"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["S1465324920300621"],"URL":"https:\/\/doi.org\/10.1016\/j.jcyt.2020.02.007","relation":{},"ISSN":["1465-3249"],"issn-type":[{"value":"1465-3249","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Autologous bone marrow mesenchymal stromal cell therapy for \u201cno-option\u201d critical limb ischemia is limited by karyotype abnormalities","name":"articletitle","label":"Article Title"},{"value":"Cytotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcyt.2020.02.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 International Society for Cell and Gene Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}